06946nam 2202041z- 450 9910404087003321202102123-03928-639-0(CKB)4100000011302268(oapen)https://directory.doabooks.org/handle/20.500.12854/58186(oapen)doab58186(EXLCZ)99410000001130226820202102d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierRenal Cell CarcinomaMDPI - Multidisciplinary Digital Publishing Institute20201 online resource (500 p.)9783039286386 Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70-80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe-oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.Biology, life sciencesbicssc11) translocation renal cell carcinomaALKAMP-activated protein kinasesanaplastic lymphoma kinase rearrangementaurora Abiomarkercancer immunotherapycancer-specific survivalCDKN1A expressioncheckpoint inhibitorschromophobe renal cell carcinomachromosomal losschronic kidney diseasecircular RNAs in a clinico-genomic predictive modelclear cell renal cell carcinomaclear cell Renal Cell Carcinomacollecting duct carcinomacopy number alterationcopy number analysiscopy number losscurcumincytoreductive nephrectomydiagnostic and prognostic markersdrug sensitivityefficacyemerging entityEMT likeeosinophilic variantESCeverolimusEVI1experimental validation of circular RNAFISHFOXO3gene expressiongene signaturegenetic associationghrelinglutathione metabolismglutathione transferase omega 1glutathione transferase omega 2glycomarkersglycoproteomicsHOThyperosmolalityidentification of circular RNAsIL-1?IL-2IL13R?1IL4R?immune checkpoint inhibitorsimmune infiltrationimmunohistochemistryimmunotherapyinflammation markersintegrinsintratumour heterogeneityinvasionJAK2kidneykidney cancerlabel-freeLOTmetabolic reprogrammingmetabolomemetabolome profilingmetastasismetastatic ccRCCmicroRNAmiR-133bmiR-146a-5pmiR-155-5pMiT family translocation renal cell carcinomaMMP-9MMP10molecular genetic featuresMTA2mTORmTOR inhibitorsmutationN-glycomappingn/anephrectomynew entityNK cellsoncocytic renal tumoroverall survivalpale cellPapillary renal cell carcinoma (pRCC)patient survivalPBRM1PD-L1pentose phosphate pathwayPI3K/Akt/mTORpolybromo-1polymorphismPPPpractical approachpredictive factorspredictive rolepro-IL-1?prognosisprognostic factorsprogrammed death-ligand 1proliferationproteome profilingRaf/MEK/ERKRCCrecurrence free survivalrecurrence-free survivalrenal cancerrenal cellrenal cell cancerrenal cell carcinomareviewRNA sequencingsarcomatoidSMAD proteinssolute carrier proteinsstatinssurvivalsurvival predictiont(6targeted therapyTCA cycleTCGATFE3TFEBTFEB-amplified renal cell carcinomatoxicitytransforming growth factor betatumor adhesiontumor microenvironmenttumor migrationtumor slice culturetyrosine kinase inhibitorsunclassified renal cell carcinomaunclassified renal tumoruric acidurineVEGF inhibitorsvon Hippel-LindauXp11 translocation renal cell carcinomaBiology, life sciencesLópez José Iauth0BOOK9910404087003321Renal Cell Carcinoma2809988UNINA